Skip to content

Discussion on the efficacy and mechanism of WMT in the treatment of Xiao ke disease (Xiao dan stage)

Discussion on the efficacy and mechanism of WMT in the treatment of Xiao ke disease (Xiao dan stage)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091173
Enrollment
Unknown
Registered
2024-10-22
Start date
2024-08-24
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Conventional treatment group:Conventional drug therapy for type 2 diabetes mellitus
WMT+conventional treatment group:WMT treatment+Conventional drug therapy for type 2 diabetes mellitus
Non-type 2 diabetes group:None

Sponsors

The First Affiliated Hospital of Guangdong Pharmaceutical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1: Conventional treatment group: meet the diagnostic criteria of T2DM in China; meet the diagnostic criteria of diabetic complications (diabetic nephropathy, diabetic peripheral neuropathy, diabetic retinopathy, diabetic angiopathy, diabetic enteropathy, and diabetic gastroparesis); and meet the diagnostic basis of Chinese medicine's "elimination and disease". 2: WMT+conventional treatment group: meet the diagnostic criteria of T2DM in China; meet the diagnostic criteria of diabetic complications (diabetic nephropathy, diabetic peripheral neuropathy, diabetic retinopathy, diabetic angiopathy, diabetic enteropathy, and diabetic gastroparesis); and meet the diagnostic basis of Chinese medicine's "elimination and disease". Patients aged 18 years or older who provide informed consent and receive routine medication for WMT and T2DM. 3: Non-T2DM group: subjects without T2DM; age =18 years, providing informed consent, and patients treated with WMT.

Exclusion criteria

Exclusion criteria: Pregnant patients; Patients taking antibiotics and probiotics 3 months before and during the trial.

Design outcomes

Primary

MeasureTime frame
fasting blood glucose;postprandial glucose;fasting insulin;postprandial insulin;glycosylated hemoglobin;16S rRNA sequencing;Short-chain fatty acids;

Secondary

MeasureTime frame
routine blood test;blood pressure;quality of life;liver function;renal function;blood lipid;routine urine test;stool for routine;

Countries

China

Contacts

Public ContactHe Xingxiang

The First Affiliated Hospital of Guangdong Pharmaceutical University

13724887928@qq.com+86 137 2488 7928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026